[go: up one dir, main page]

MA48751A - Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax - Google Patents

Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax

Info

Publication number
MA48751A
MA48751A MA048751A MA48751A MA48751A MA 48751 A MA48751 A MA 48751A MA 048751 A MA048751 A MA 048751A MA 48751 A MA48751 A MA 48751A MA 48751 A MA48751 A MA 48751A
Authority
MA
Morocco
Prior art keywords
treatment
venetoclax
antibodies
paradigm
combined
Prior art date
Application number
MA048751A
Other languages
English (en)
Other versions
MA48751B1 (fr
Inventor
Steffen Heeger
Peter Kelemen
Michael Schwarz
Dominika Weinelt
Mark Winderlich
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MA48751A publication Critical patent/MA48751A/fr
Publication of MA48751B1 publication Critical patent/MA48751B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA48751A 2017-05-31 2018-05-30 Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax MA48751B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173712 2017-05-31
PCT/EP2018/064229 WO2018220040A1 (fr) 2017-05-31 2018-05-30 Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax

Publications (2)

Publication Number Publication Date
MA48751A true MA48751A (fr) 2020-04-08
MA48751B1 MA48751B1 (fr) 2023-11-30

Family

ID=59070416

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48751A MA48751B1 (fr) 2017-05-31 2018-05-30 Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax

Country Status (26)

Country Link
US (1) US20250186460A1 (fr)
EP (2) EP4268900A3 (fr)
JP (2) JP7399713B2 (fr)
KR (2) KR20240117655A (fr)
CN (1) CN110678201A (fr)
AU (2) AU2018276384B2 (fr)
BR (1) BR112019025034A2 (fr)
CA (1) CA3062400A1 (fr)
DK (1) DK3630177T5 (fr)
ES (1) ES2961940T3 (fr)
FI (1) FI3630177T3 (fr)
HR (1) HRP20231229T1 (fr)
HU (1) HUE063119T2 (fr)
IL (2) IL297461B2 (fr)
LT (1) LT3630177T (fr)
MA (1) MA48751B1 (fr)
MD (1) MD3630177T2 (fr)
MX (2) MX2019014330A (fr)
PL (1) PL3630177T3 (fr)
PT (1) PT3630177T (fr)
RS (1) RS64746B1 (fr)
SG (1) SG11201909715VA (fr)
SI (1) SI3630177T1 (fr)
SM (1) SMT202300338T1 (fr)
WO (1) WO2018220040A1 (fr)
ZA (1) ZA201907369B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954388A1 (fr) 2015-08-21 2022-02-16 MorphoSys AG Combinaisons et leurs utilisations
IL320372A (en) 2016-10-28 2025-06-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2023551519A (ja) * 2020-11-30 2023-12-08 インサイト・コーポレイション 抗ｃｄ１９抗体とパルサクリシブの組み合わせ療法
WO2022115120A1 (fr) * 2020-11-30 2022-06-02 Incyte Corporation Polythérapie comprenant un anticorps anti-cd19 et le parsaclisib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (fr) 2003-07-31 2015-04-22 Immunomedics, Inc. Anticorps anti-CD19
KR20080032097A (ko) 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
HRP20140331T1 (hr) 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
EP2398829A2 (fr) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Anticorps humanisés qui se fixent au cd19 et leurs utilisations
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
MX354479B (es) 2011-08-16 2018-03-07 Morphosys Ag Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
KR102117202B1 (ko) 2011-08-16 2020-06-01 모르포시스 아게 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
EP3954388A1 (fr) 2015-08-21 2022-02-16 MorphoSys AG Combinaisons et leurs utilisations
IL320372A (en) 2016-10-28 2025-06-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and uses thereof

Also Published As

Publication number Publication date
IL270855B2 (en) 2023-03-01
AU2018276384B2 (en) 2025-02-13
EP4268900A3 (fr) 2024-03-06
IL297461A (en) 2022-12-01
KR20240117655A (ko) 2024-08-01
BR112019025034A2 (pt) 2020-06-30
IL270855A (en) 2020-01-30
SI3630177T1 (sl) 2023-12-29
AU2018276384A1 (en) 2019-11-07
WO2018220040A1 (fr) 2018-12-06
US20250186460A1 (en) 2025-06-12
HRP20231229T1 (hr) 2024-02-02
KR20200010472A (ko) 2020-01-30
CA3062400A1 (fr) 2018-12-06
IL297461B2 (en) 2024-09-01
MD3630177T2 (ro) 2024-01-31
MA48751B1 (fr) 2023-11-30
EP3630177B1 (fr) 2023-08-09
AU2025203436A1 (en) 2025-06-05
MX2019014330A (es) 2020-02-05
ZA201907369B (en) 2024-04-24
FI3630177T3 (fi) 2023-10-18
RU2019139552A (ru) 2021-07-01
SG11201909715VA (en) 2019-11-28
IL270855B (en) 2022-11-01
EP3630177A1 (fr) 2020-04-08
PT3630177T (pt) 2023-11-10
EP4268900A2 (fr) 2023-11-01
SMT202300338T1 (it) 2023-11-13
IL297461B1 (en) 2024-05-01
MX2023013228A (es) 2024-04-16
ES2961940T3 (es) 2024-03-14
JP2024028865A (ja) 2024-03-05
PL3630177T3 (pl) 2024-04-08
JP2020521777A (ja) 2020-07-27
RU2019139552A3 (fr) 2021-09-22
DK3630177T5 (da) 2024-09-02
HUE063119T2 (hu) 2024-01-28
RS64746B1 (sr) 2023-11-30
CN110678201A (zh) 2020-01-10
DK3630177T3 (da) 2023-10-16
LT3630177T (lt) 2023-10-25
JP7399713B2 (ja) 2023-12-18

Similar Documents

Publication Publication Date Title
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA49394A (fr) Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps
EP4261231A4 (fr) Anticorps bispécifique et application correspondante
EP3797123A4 (fr) Anticorps anti-ox40 et procédés d'utilisation
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA48751A (fr) Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
EP3328429A4 (fr) Peptides et anticorps pour l'élimination de biofilms
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3573658A4 (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
EP3414573A4 (fr) Nouveaux anticorps monoclonaux anti-lam et anti-pim6/lam pour le diagnostic et le traitement d'infections par le bacille de koch
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
EP3713955A4 (fr) Anticorps anti-ifnar1 pour le traitement de maladies auto-immunes
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3733713A4 (fr) Anticorps bispécifique et ses applications
EP3863671A4 (fr) Anticorps monoclonal pour le traitement de la leucémie lymphoblastique aiguë
EP3397262A4 (fr) Combinaison d'inhibiteur de hdac et d'anticorps anti-pd-l1 pour le traitement de cancer des ovaires